Isaksenyu9939

n.

Analysis of conservation of gene neighbourhoods over different evolutionary levels is important for understanding operon and gene cluster evolution, and predicting functional associations. Our tool FlaGs (Flanking Genes) takes a list of NCBI protein accessions as input, clusters neighbourhood-encoded proteins into homologous groups using sensitive sequence searching, and outputs a graphical visualization of the gene neighbourhood and its conservation, along with a phylogenetic tree annotated with flanking gene conservation. FlaGs has demonstrated utility for molecular evolutionary analysis, having uncovered a new toxin-antitoxin system in prokaryotes and bacteriophages. The web version of FlaGs (webFlaGs) can optionally include a BLASTP search against a reduced RefSeq database to generate an input accession list and analyse neighbourhood conservation within the same run.

FlaGs can be downloaded from https//github.com/GCA-VH-lab/FlaGs or run online at http//www.webflags.se/.

Supplementary data are available at Bioinformatics online.

Supplementary data are available at Bioinformatics online.

To investigate the efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention (PCI) stratified according to the baseline white blood cell (WBC) count.

This is a post-hoc analysis of the GLOBAL LEADERS trial, a multicentre, open-label, randomized all-comer trial in patients undergoing PCI, comparing the experimental strategy (23-month ticagrelor monotherapy following 1-month dual anti-platelet therapy [DAPT]) with the reference strategy (12-month aspirin monotherapy following 12-month DAPT). Patients were stratified into two WBC groups, either < or ≥median WBC count of 7.8 x 109 cells/L (lower or higher WBC group, respectively). The primary endpoint was a composite of all-cause mortality or new Q-wave myocardial infarction (MI) at 2 years.Out of 14,576 patients included in the present study, 7,212 patients (49.5%) were classified as the lower WBC group, who had a significantly lower risk of both ischemic and bleeding outcomes at 2 years. At 2 years, the experimental strategy was associated with a significant lower incidence of the primary endpoint compared with the reference strategy in the lower WBC group (2.8% vs. 4.2%; hazard ratio [HR] 0.67; 95% CI 0.52-0.86) but not in the higher WBC group (4.8% vs. 4.7%; HR 1.01; 95% CI 0.82-1.25; pinteraction=0.013). There were no significant differences in the risks of BARC type 3 or 5 bleeding between two antiplatelet strategies regardless of the WBC groups.

Increased WBC counts, which may reflect degree of inflammation, at the time of index procedure may attenuate the anti-ischemic benefits of ticagrelor monotherapy observed in patients with lower WBC counts.

Increased WBC counts, which may reflect degree of inflammation, at the time of index procedure may attenuate the anti-ischemic benefits of ticagrelor monotherapy observed in patients with lower WBC counts.Many enzymes that catalyze protein post-translational modifications can specifically modify multiple target proteins. However, little is known regarding the molecular basis and evolution of multispecificity in these enzymes. Here, we used a combined bioinformatics and experimental approaches to investigate the evolution of multispecificity in the sirtuin-1 (SIRT1) deacetylase. Guided by bioinformatics analysis of SIRT1 orthologs and substrates, we identified and examined important amino acid substitutions that have occurred during the evolution of sirtuins in Metazoa and Fungi. We found that mutation of human SIRT1 at these positions, based on sirtuin orthologs from Fungi, could alter its substrate specificity. These substitutions lead to reduced activity toward K382 acetylated p53 protein, which is only present in Metazoa, without affecting the high activity toward the conserved histone substrates. Results from ancestral sequence reconstruction are consistent with a model in which ancestral sirtuin proteins exhibited multispecificity, suggesting that the multispecificity of some metazoan sirtuins, such as hSIRT1, could be a relatively ancient trait.Acetamide, a food contaminant, has been shown to induce hepatocellular tumors in rats. However, the mode of action underlying acetamide-induced hepatocarcinogenesis remains unclear. In the current study, we aimed to examine the possible involvement of in vivo mutagenicity in hepatocarcinogenesis of acetamide and evaluate its toxicological profile using a comprehensive medium-term toxicity study in gpt delta rats. Six-week-old male F344 gpt delta rats were given a basal diet containing 0%, 0.625%, 1.25%, or 2.5% acetamide for 13 weeks. In general toxicologic assessment, hepatotoxic parameters in serum, such as aspartate aminotransferase and alanine aminotransferase were significantly changed at the 1.25% group and higher. see more of the liver revealed that various changes related to hepatic injury were observed at the 1.25% group and higher. Interestingly, Feulgen-positive cytoplasmic inclusion was frequently observed in hepatocytes in these groups. In the hematopoietic system, red blood cell parameters in plasma, such as mean corpuscular volume and mean corpuscular hemoglobin were significantly changed at the 1.25% group and higher, and decrease of erythroblast in the spleen was observed histopathologically in the 2.5% group. #link# Thus, the no-observed-adverse-effect level of acetamide in this study was 0.625% (equivalent to 394 mg/kg body weight/day). In vivo mutation assays showed that acetamide induced no changes in gpt and red/gam gene mutant frequencies, even at the carcinogenic target site. In contrast, Ki67-positive hepatocytes were increased significantly at carcinogenic doses. Therefore, these results suggested that cell proliferation activity, but not mutagenicity, played crucial roles in acetamide-induced hepatocarcinogenesis in rats.

Current treatment guidelines recommend implantable cardioverter-defibrillators (ICDs) in eligible patients with an estimated survival beyond one year. There is still an unmet need to identify patients who are unlikely to benefit from an ICD.We determined cause-specific one-year mortality after ICD implantation and identified associated risk factors.

Using Danish nationwide registries (2000-2017), we identified 14,516 patients undergoing first-time ICD implantation for primary or secondary prevention. Risk factors associated with one-year mortality were evaluated using multivariable logistic regression. The median age was 66 years, 81.3% were male, and 50.3% received an ICD for secondary prevention. The one-year mortality rate was 4.8% (694/14,516). ICD recipients who died within one year were older and more comorbid compared to those who survived (72 vs. 66 years, p < 0.001). Risk factors associated with increased one-year mortality included dialysis (OR3.26, CI2.37-4.49), chronic renal disease (OR2.14, CI1.